Cargando…

A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene

BACKGROUND: The hepatocyte growth factor (HGF)/c-Met signal pathway is up-regulated in human mesothelioma and suppression of the HGF/c-Met signaling with a competitive inhibitor, NK4 homologous to HGF in the structure, produced anti-tumor effects to mesothelioma in a preclinical study. Mesothelioma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tada, Yuji, Hiroshima, Kenzo, Shimada, Hideaki, Morishita, Naoya, Shirakawa, Toshiro, Matsumoto, Kunio, Shingyoji, Masato, Sekine, Ikuo, Tatsumi, Koichiro, Tagawa, Masatoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503710/ https://www.ncbi.nlm.nih.gov/pubmed/26191485 http://dx.doi.org/10.1186/s40064-015-1123-3

Ejemplares similares

An intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocol
por: Tada, Yuji, et al.
Publicado: (2016)

Combination of a third generation bisphosphonate and replication-competent adenoviruses augments the cytotoxicity on mesothelioma
por: Jiang, Yuanyuan, et al.
Publicado: (2016)

Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways
por: Shimazu, Kengo, et al.
Publicado: (2017)

Cytotoxic effects of replication-competent adenoviruses on human esophageal carcinoma are enhanced by forced p53 expression
por: Yang, Shan, et al.
Publicado: (2015)

An image cytometric technique is a concise method to detect adenoviruses and host cell proteins and to monitor the infection and cellular responses induced
por: Morinaga, Takao, et al.
Publicado: (2017)

Cytotoxicity of replication-competent adenoviruses powered by an exogenous regulatory region is not linearly correlated with the viral infectivity/gene expression or with the E1A-activating ability but is associated with the p53 genotypes
por: Yamauchi, Suguru, et al.
Publicado: (2017)

Zoledronic Acid Produces Combinatory Anti-Tumor Effects with Cisplatin on Mesothelioma by Increasing p53 Expression Levels
por: Okamoto, Shinya, et al.
Publicado: (2013)

An MDM2 inhibitor achieves synergistic cytotoxic effects with adenoviruses lacking E1B55kDa gene on mesothelioma with the wild-type p53 through augmenting NFI expression
por: Nguyen, Thao Thi Thanh, et al.
Publicado: (2021)

Interferon-β Produces Synergistic Combinatory Anti-Tumor Effects with Cisplatin or Pemetrexed on Mesothelioma Cells
por: Li, Quanhai, et al.
Publicado: (2013)

A Potential Therapeutic Strategy for Malignant Mesothelioma with Gene Medicine
por: Tada, Yuji, et al.
Publicado: (2013)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
por: Qin, Yiyang, et al.
Publicado: (2017)

Zoledronic acid induces apoptosis and S-phase arrest in mesothelioma through inhibiting Rab family proteins and topoisomerase II actions
por: Okamoto, S, et al.
Publicado: (2014)

Mesenchymal stem cells are efficiently transduced with adenoviruses bearing type 35-derived fibers and the transduced cells with the IL-28A gene produces cytotoxicity to lung carcinoma cells co-cultured
por: Suzuki, Takeo, et al.
Publicado: (2014)

Fas Ligand DNA Enhances a Vaccination Effect by Coadministered DNA Encoding a Tumor Antigen through Augmenting Production of Antibody against the Tumor Antigen
por: Zhong, Boya, et al.
Publicado: (2015)

Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin
por: Ak, Guntulu, et al.
Publicado: (2017)

Heat shock protein 90 inhibitors augment endogenous wild-type p53 expression but down-regulate the adenovirally-induced expression by inhibiting a proteasome activity
por: Chai, Kuan, et al.
Publicado: (2018)

HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis
por: Gaudino, Giovanni, et al.
Publicado: (2014)

Diffuse pleural thickening and thoracic contraction: An indistinguishable case from malignant pleural mesothelioma
por: Tada, Yuji, et al.
Publicado: (2020)

HGF–Met Pathway in Regeneration and Drug Discovery
por: Matsumoto, Kunio, et al.
Publicado: (2014)

Cyclic Peptide-Based Biologics Regulating HGF-MET
por: Sato, Hiroki, et al.
Publicado: (2020)

AMPK activation induced in pemetrexed‐treated cells is associated with development of drug resistance independently of target enzyme expression
por: Qin, Yiyang, et al.
Publicado: (2019)

Gene medicine for cancer treatment: Commercially available medicine and accumulated clinical data in China
por: Ma, Guangyu, et al.
Publicado: (2009)

A Possible Anticancer Agent, Type III Interferon, Activates Cell Death Pathways and Produces Antitumor Effects
por: Tagawa, Masatoshi, et al.
Publicado: (2011)

Dimer Interface in Natural Variant NK1 Is Dispensable for HGF-Dependent Met Receptor Activation
por: Tahira, Yumiko, et al.
Publicado: (2021)

HGF-MET as a breast cancer biomarker
por: Liu, Shuying
Publicado: (2015)

HGF/c-MET Signaling in Melanocytes and Melanoma
por: Czyz, Malgorzata
Publicado: (2018)

HGF/Met Axis in Heart Function and Cardioprotection
por: Gallo, Simona, et al.
Publicado: (2014)

Physiological Signaling and Structure of the HGF Receptor MET
por: Baldanzi, Gianluca, et al.
Publicado: (2014)

HGF/MET Signaling in Malignant Brain Tumors
por: Mulcahy, Elizabeth Qian Xu, et al.
Publicado: (2020)

Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion
por: Cao, Hui-Hui, et al.
Publicado: (2015)

Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
por: Goey, S. H., et al.
Publicado: (1995)

Immune responses following intrapleural administration of oncolytic SEPREHVIR in patients with malignant pleural mesothelioma
por: Learmonth, Kirsty, et al.
Publicado: (2015)

HGF-independent Potentiation of EGFR Action by c-Met
por: Dulak, Austin M., et al.
Publicado: (2011)

Targeting the HGF-cMET Axis in Hepatocellular Carcinoma
por: Venepalli, Neeta K., et al.
Publicado: (2013)

The role of HGF/c-MET signaling pathway in lymphoma
por: Lam, Bao Quoc, et al.
Publicado: (2016)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma
por: Cruickshanks, Nichola, et al.
Publicado: (2017)

The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma
por: Wang, Haiyu, et al.
Publicado: (2020)

Targeting HGF/c-MET Axis in Pancreatic Cancer
por: Pothula, Srinivasa P., et al.
Publicado: (2020)

The Role of HGF/MET Signaling in Metastatic Uveal Melanoma
por: Tanaka, Ryota, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5e923hd7mtit8mekn60jdsceke